Article
Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.
American journal of hematology - 1 Jun 2025
Barbui Tiziano, Stefano Valerio De, Rossi Elena, Ghirardi Arianna, Carobbio Alessandra, Loscocco Giuseppe Gaetano, Condorelli Annalisa, Guglielmelli Paola
Abstract excerpt
This paper explores emerging therapies in polycythemia vera and essential thrombocythemia, focusing on thrombosis as a driver of disease progression leading to myelofibrosis, blast phase, second cancers, and mortality. While the thrombosis rate in high-risk patients has declined, it remains persistently high in low-risk individuals, with most events being arterial. Inflammation driven by JAK2 V617F mutation plays...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.